Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference

Rhea-AI Summary

Annexon (Nasdaq: ANNX) announced that Douglas Love, president and chief executive officer, will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 9:50 a.m. ET.

A live webcast will be available via the company’s Investors "Events & Presentations" page and a replay will be archived for 30 days following the presentation.

News Market Reaction – ANNX

+1.43%

2 alerts

+1.43% News Effect

+23.6% Peak Tracked

+$10M Valuation Impact

$717M Market Cap

3K Volume

On the day this news was published, ANNX gained 1.43%, reflecting a mild positive market reaction. Argus tracked a peak move of +23.6% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $10M to the company's valuation, bringing the market cap to $717M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Patient population impacted: 10 million people worldwide Conference date: March 3, 2026 Presentation time: 9:50 a.m. ET +1 more

4 metrics

Patient population impacted 10 million people worldwide Neuroinflammatory diseases targeted by Annexon platform

Conference date March 3, 2026 TD Cowen 46th Annual Health Care Conference presentation

Presentation time 9:50 a.m. ET Scheduled time for TD Cowen conference presentation

Webcast replay period 30 days Replay archived on Annexon website following presentation

Market Reality Check

Price: $5.43 Vol: Volume 1,585,684 vs 20-da...

normal vol

$5.43 Last Close

Volume Volume 1,585,684 vs 20-day average 2,037,253 ahead of conference appearance. normal

Technical Price $4.89 trading above 200-day MA at $3.44, indicating a pre-news uptrend.

Peers on Argus

Sector peers showed mixed moves, with some up and some down; only LCTX appeared ...

1 Up

Sector peers showed mixed moves, with some up and some down; only LCTX appeared in momentum scans, suggesting this conference update is more company-specific than part of a broad sector move.

Common Catalyst Multiple neuro-focused biotechs, including ALEC, announced participation in the TD Cowen 46th Annual Health Care Conference.

Historical Context

5 past events · Latest: Feb 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 17	KOL event announcement	Positive	+3.1%	Announced March KOL event and timeline for ARCHER II Phase 3 topline data.
Jan 16	Inducement grants	Neutral	+1.5%	Reported stock option inducement awards to new employees under Nasdaq rules.
Jan 12	Pipeline priorities	Positive	+5.9%	Outlined 2026 platform milestones, including MAA filing and key trial readouts.
Jan 8	EMA MAA submission	Positive	-4.3%	Submitted MAA to EMA for tanruprubart in Guillain-Barré syndrome.
Jan 7	JPM conference presentation	Positive	+8.4%	Announced upcoming presentation at the J.P. Morgan Healthcare Conference.

Pattern Detected

Recent company updates, including conferences and pipeline milestones, most often coincided with positive price reactions, with one notable divergence on a major regulatory filing.

Recent Company History

Over the last few months, Annexon has highlighted several milestones: an upcoming GA-focused KOL event with ARCHER II Phase 3 data expected in the second half of 2026, inducement grants to new hires, and a 2026 priorities update featuring a European MAA for tanruprubart and completed enrollment in the ARCHER II trial. A prior J.P. Morgan conference presentation also drew interest. Against this backdrop, the TD Cowen conference appearance extends ongoing investor outreach and communication efforts.

Market Pulse Summary

This announcement highlights Annexon’s planned presentation at the TD Cowen 46th Annual Health Care ...

Analysis

This announcement highlights Annexon’s planned presentation at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, extending a pattern of active investor engagement. It follows recent updates on 2026 milestones, including European MAA progress and key Phase 3 timelines. Investors may focus on any incremental color about the neuroinflammatory franchise, including programs affecting nearly 10 million patients, and how management frames upcoming clinical and regulatory catalysts during the webcast.

Key Terms

neuroinflammatory, immunotherapies, webcast

3 terms

neuroinflammatory medical

"immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people"

Neuroinflammatory describes inflammation occurring in the brain, spinal cord or peripheral nerves when the body's immune response becomes active in nervous tissue. For investors, it matters because neuroinflammatory processes are central to many neurological diseases and can drive demand for new drugs, affect clinical trial outcomes, and influence regulatory decisions—similar to how a neighborhood dispute can change local services and property values, inflammation can reshape treatment needs and company prospects.

immunotherapies medical

"advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases"

Immunotherapies are medical treatments that strengthen or guide the body's own immune system to recognize and fight disease cells, such as cancer or chronic infections. They matter to investors because they can produce long-lasting patient responses, command premium prices, and reshape standard care—similar to installing a smarter security system that prevents repeat break-ins—creating significant commercial upside but also clinical and regulatory risk.

webcast technical

"A live webcast of the event can be accessed under the ‘Events & Presentations’ section"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. Not financial advice.

BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president and chief executive officer, will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 9:50 a.m. ET.

A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.

About Annexon

Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.

Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com

Media Contact:
Beth Keshishian
917-912-7195
beth@bethkeshishian.com

FAQ

When will Annexon (ANNX) present at the TD Cowen 46th Annual Health Care Conference?

Annexon (ANNX) will present on March 3, 2026 at 9:50 a.m. ET. According to Annexon, Douglas Love, president and CEO, will deliver the presentation and address company strategy and recent developments to conference attendees and investors.

How can investors watch the Annexon (ANNX) presentation on March 3, 2026?

Investors can watch a live webcast through Annexon’s Investors "Events & Presentations" page. According to Annexon, the webcast will stream live and a replay will be archived on the company website for 30 days after the event.

Who is presenting for Annexon (ANNX) at the TD Cowen conference on March 3, 2026?

Douglas Love, president and chief executive officer, will present for Annexon (ANNX). According to Annexon, he will outline corporate priorities and provide updates during his scheduled 9:50 a.m. ET slot on March 3, 2026.

Will a replay of the Annexon (ANNX) March 3, 2026 presentation be available after the conference?

Yes, a replay will be available and archived for 30 days on the company website. According to Annexon, the archived webcast can be accessed via the Investors "Events & Presentations" page following the live event.